# Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients

> **NCT04529499** · PHASE3 · TERMINATED · sponsor: **Dr. Reddy's Laboratories Limited** · enrollment: 353 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** AVIGAN
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT04529499
- **Lead sponsor:** Dr. Reddy's Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-22
- **Primary completion:** 2021-01-22
- **Final completion:** 2021-01-27
- **Target enrollment:** 353 (ACTUAL)
- **Why stopped:** Study met pre-defined criteria for futility at interim analysis
- **Last updated:** 2022-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04529499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04529499, "Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04529499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*